HK Stock Market Move | Today, Joinn Laboratories China (02225) surged by over 11%, and its subsidiary signed a sales agreement with China National Pharmaceutical Group Corporation, accelerating the commercialization process of high-end medical devices.

Today, Hoi Yai Medical Technology (02225) rose by more than 11%, rising 11.11% to $1.5 Hong Kong dollars, with a turnover of 3.8556 million Hong Kong dollars as of press time. In terms of news, recently Hoi Yai Medical Technology announced that its wholly-owned subsidiary, Hoi Yai Xie Huan, has recently entered into a sales agreement with Guoyao Ling, a company. According to the agreement, Hoi Yai Xie Huan authorizes Guoyao Ling to be the exclusive distributor for a number of high-end medical equipment of the group in China, with the term expiring in October of this year. With Guoyao Ling's extensive distribution network and strong market influence, the group's main products are expected to have a broader market presence and achieve rapid growth. Especially, the group's 4K3D fluorescence endoscope, intervertebral foramen endoscope, and supporting instruments have shown strong market competitiveness and growth potential. In the first half of 2024, Hoi Yai Medical achieved revenue of 25.937 million Singapore dollars, a year-on-year increase of 116.45%. Among them, revenue from minimally invasive surgical solutions and medical products and related service fees increased from 400,000 Singapore dollars in the first half of 2023 to 12.3 million Singapore dollars in the first half of 2024. In terms of technological reserves, Hoi Yai Medical has over 60 patents, over 20 trademarks, and more than 30 projects under research. In the "Minimally Invasive 4.0 Era", Hoi Yai Medical's basic technology is leading comprehensively, with existing technologies including three/four chips, naked-eye 3D, 4K, 3D, and fluorescence.